Conference Reports for NATAP

Back

11th International Congress on Drug Therapy in HIV Infection 11-15 November 2012 Glasgow, UK     Raltegravir switch improves Hepatitis C transaminitis in HIV-1 and Hepatitis C (HCV) co-infected individuals - (11/29/12)   Total and Unbound Darunavir (DRV) Pharmacokinetics (PK) in HIV-1-Infected Pregnant Women - (11/26/12)   Generalised additive model analysis of the relationship between darunavir pharmacokinetics and pharmacodynamics following once-daily darunavir/ ritonavir 800/100mg treatment in the Phase III trials, ARTEMIS and ODIN - (11/26/12)   Rilpivirine efficacy, virology and safety in antiretroviral treatment-naïve patients with baseline viral load ≤100,000 HIV-1 RNA copies/mL: ECHO and THRIVE 96-week pooled dataset - (11/26/12)   Enabling clinical development of an HIV attachment inhibitor through innovative pharmaceutical development: novel extended-release delivery of a prodrug - (11/20/12)   Genotypic and phenotypic correlates of virologic response to the attachment inhibitor BMS-626529 in a short-term monotherapy study with its prodrug BMS-663068 - (11/20/12)   The HIV NRTI BMS-986001 does not degrade mitochondrial DNA in long-term primary cultures of cells isolated from human kidney, muscle and subcutaneous fat - (11/20/12)   STaR Study: Single-Tablet Regimen Emtricitabine/Rilpivirine/Tenofovir DF is Non-Inferior to Efavirenz/Emtricitabine/Tenofovir DF in ART-Naïve Adults Week 48 Results - (11/16/12)   Gilead 's Complera® Non-Inferior to Atripla® Among Treatment-Naïve HIV Patients - (11/16/12)   Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (STB) Has Durable Efficacy and Differentiated Safety Compared to Efavirenz/Emtricitabine/Tenofovir DF (ATR) in Treatment-naïve HIV-1 Infected Patients: Week 96 Results - (11/16/12)   Gilead 's Once-Daily Single Tablet Regimen Stribild™ Maintains High Viral Suppression Through Two Years of Therapy Among Treatment-Naïve HIV Patients - press release - (11/16/12)   Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF (STB) Has Durable Efficacy and Differentiated Safety Compared to Atazanavir Boosted by Ritonavir Plus Emtricitabine/Tenofovir DF in Treatment-naïve HIV-1 Infected Patients: Week 96 Results - (11/16/12)   Safety & Efficacy of Raltegravir in Patients Co-infected with HIV and Hepatitis B and/or C Virus: Complete Data from Phase III Double-Blind Studies - (11/16/12)   ISENTRESS® (raltegravir) in Combination Therapy Demonstrated Long-Term Efficacy and Safety in Adult Patients Co-Infected with HIV-1 and Hepatitis B and/or C in a Subgroup Analysis at 240 Weeks - (11/16/12)   ViiV Healthcare presents phase III data from VIKING-3 study of dolutegravir in HIV-1 infected integrase inhibitor-resistant adults - (11/16/12)   Antiviral Activity of Dolutegravir in Subjects with Failure on an Integrase Inhibitor-Based Regimen: Week 24 Phase 3 Results from VIKING-3 (2) Oral - (11/16/12)   Antiviral Activity of Dolutegrevir in Subjects With Failure on an Integrase Inhibitor-Based Regimen: Week 24 Phase 3 Results From VIKING-3 (1) Poster - (11/16/12)   Increasing Subject Compliance in Pivotal Phase III Clinical Trials of Dolutegravir (DTG, S/GSK1349572) in HIV-Infected, ART-Naive Subjects - (11/16/12)   Dolutegravir Treatment Response by Baseline Viral Load and NRTI Backbone in Treatment-Naive, HIV-Infected Individuals - (11/16/12)   LONG TERM DURABILITY OF NEVIRAPINE BASED ART IN A COHORT OF 84 PATIENTS AFTER INDUCTION WITH PROTEASE INHIBITOR TREATMENT - (11/16/12)   Long-term (96 and 144 Week) Efficacy and Safety From the VERxVE Trial Comparing Nevirapine Extended-Release (NVP XR) 400 mg Once a Day to Nevirapine Immediate- Release (NVP IR) 200 mg Twice a Day in Combination With Emtricitabine/Tenofovir in Treatment-Naïve HIV-1 Patients - (11/16/12)